- Home
- ADUR vs CADL Comparison
ADUR vs CADL Comparison
Compare ADUR & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADUR
- CADL
- Stock Information
- Founded
- ADUR 2011
- CADL 1999
- Country
- ADUR Canada
- CADL United States
- Employees
- ADUR N/A
- CADL N/A
- Industry
- ADUR
- CADL Biotechnology: Pharmaceutical Preparations
- Sector
- ADUR
- CADL Health Care
- Exchange
- ADUR NYSE
- CADL Nasdaq
- Market Cap
- ADUR 154.9M
- CADL 159.1M
- IPO Year
- ADUR N/A
- CADL 2021
- Fundamental
- Price
- ADUR $6.13
- CADL $9.17
- Analyst Decision
- ADUR
- CADL Strong Buy
- Analyst Count
- ADUR 0
- CADL 1
- Target Price
- ADUR N/A
- CADL $19.00
- AVG Volume (30 Days)
- ADUR 66.1K
- CADL 9.7M
- Earning Date
- ADUR 01-01-0001
- CADL 11-14-2024
- Dividend Yield
- ADUR N/A
- CADL N/A
- EPS Growth
- ADUR N/A
- CADL N/A
- EPS
- ADUR N/A
- CADL N/A
- Revenue
- ADUR $247,485.00
- CADL N/A
- Revenue This Year
- ADUR N/A
- CADL N/A
- Revenue Next Year
- ADUR N/A
- CADL N/A
- P/E Ratio
- ADUR N/A
- CADL N/A
- Revenue Growth
- ADUR 98.59
- CADL N/A
- 52 Week Low
- ADUR $1.34
- CADL $1.16
- 52 Week High
- ADUR $7.00
- CADL $14.60
- Technical
- Relative Strength Index (RSI)
- ADUR N/A
- CADL 62.67
- Support Level
- ADUR N/A
- CADL $7.90
- Resistance Level
- ADUR N/A
- CADL $10.38
- Average True Range (ATR)
- ADUR 0.00
- CADL 1.79
- MACD
- ADUR 0.00
- CADL 0.30
- Stochastic Oscillator
- ADUR 0.00
- CADL 46.66
About ADUR ADURO CLEAN TECHNOLOGIES INC
Aduro Clean Technologies Inc is a developer of patented water-based technologies to chemically recycle plastics and transform heavy crude and renewable oils into feedstocks and higher-value fuels. The company's technology activates unique properties of water in a chemistry platform that operates at relatively low temperatures and costs.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.